The Country Can’t Survive a Third Obama
The Country Can’t Survive a Third Obama Term
Supporting Donald Trump is a bitter pill for many conservatives and libertarians to swallow.
But, to the two of us, a Republican and a recently declared independent, it is ultimately the only defensible decision if our votes are to make any difference on November 8.
No one should consider staying home on Election Day.
Voting third party, while attractive on the psychological level and, perhaps, superficially gratifying on a moral level, is a self-indulgent luxury we cannot afford in 2016.
Either Donald Trump or the Clintons will be the next President of the United States. The certainties that come with electing the Clintons overshadow both the known flaws and the uncertainties of a President Trump.
One of us left the Republican Party in 2015, not in protest over Donald Trump’s lack of a credible track record on issues conservatives care about, but over the Republican establishment’s betrayal of the party’s principles, platform and unwillingness to oppose Obama’s unconstitutional power grabs.
The other was a pledged Ted Cruz delegate to the Republican National Convention in Cleveland, who supported the floor walkout over RNC hijinks on convention procedures and rules, and has since expressed serious doubts over Donald Trump’s temperament, history and policy flip-flops.
We still have many of those doubts about both Trump’s fitness and the Republican Party’s commitment to carry out Trump’s promises, especially on border control, Islamic terrorism, and Supreme Court appointments.
Nevertheless, while those doubts and concerns remain, they pale into insignificance when compared to the absolute certainty of the fate that awaits constitutional liberty under the “progressive” rule of Hillary Clinton.
Take the Supreme Court vacancies as an example of the real-world choice we face in November.
Are we 100 percent confident that Donald Trump will appoint true constitutionalist judges to fill court vacancies? No. But we are 100% certain that Hillary Clinton will appoint progressive judges who will undermine the 2nd Amendment and other essential freedoms.
Are we 100 percent certain that Donald Trump will build a border fence, enforce our immigration laws and say no to another general amnesty? No, we can’t be 100 percent certain of that.
But we know that Hillary Clinton will continue and probably even expand Obama’s outrageous dismantling of immigration law enforcement.She says so.
We could list a dozen other important issues where Trump may disappoint us by not following through on his promises, and a few other issues where his policies remain murky at best. But on those issues most important to constitutional conservatives, Donald Trump is significantly more likely to follow a conservative path than Hillary Clinton.
The new “progressive” Democrats have even stopped pretending to respect the Constitution. To them, it’s just an old piece of paper made obsolete by history and multiculturalism.
The Democrat Party of Truman and JFK is dead, replaced by an openly socialist party committed to massive income redistribution and “global citizenship.”
Trump has tapped into the concerns and frustrations of those alienated Republicans and “Blue Dog Democrats” whose parties are now unrecognizable to them.
He has surrounded himself with and listens to other strong voices who, whether they pass the constitutional conservative purity test or not, fully support his never-wavering mantra of America First.
He has imperfectly, but significantly, adapted his behaviors and his rhetoric to his new role as potential future president.
These actions and more, plus the support of a fast-growing number of true movement conservatives, border patrol agents, police fraternities, Tea Party Patriots, military heroes, wildly changing and favorable polling, and the voices that have been pushing us all along–all have made the case for Donald Trump.
And the thought (nightmare) of President Hillary and First (whatever) Bill Clinton seals the deal.
The Republican Party is at a crossroads, and many of the Old Guard and the insiders of the Washington establishment (what Ted Cruz rightfully refers to as the “cartel”), are openly supporting Hillary Clinton.
Why? Because she does not threaten the status quo. Donald Trump does. Well, we say, good riddance, and we pray that Trump really does mean to turn DC on its head! We know that Hillary will not.
For months now since the Cleveland convention, both of us have been saying about Donald Trump that we will probably hold our nose and vote for him despite our misgivings.
Because of Trump’s contradictory past, many conservatives will be doing that on November 8.
If that is the best you can do, so be it. But, we have concluded that with so much at stake, a reluctant vote is not enough.
With Donald Trump we at least have a shot at preserving our Constitution. That leads us to stand up and say: Donald Trump, we see that your glass is only half full.
But, to a nation dying on the desert of Political Correctness, that is salvation enough. We would rather spend the next four years fighting a potentially dying Party and an America First President, though both are not well-grounded in our principles, than figuring out how to survive a third Obama term run by the feeble, dishonest, Alinskyite heads of the now-exposed (for those who care to see) Clinton dynasty.
There is a very small space between #NeverHillary and #NeverTrump. It’s called the voting booth. The debates are coming and Election Day is approaching fast. Let’s fire it up. Let’s give our nation a fighting chance.
Let’s win with Trump.
Randy Corporon is a Colorado attorney, former radio talk show host, Tea Party leader, Cruz delegate to the Cleveland convention, and an outspoken critic of the Republican nominee.Tom Tancredo is a former Republican congressman and presidential candidate from Colorado.
Featured stocks: Coffee Shoppe
For conservative debate: "Keeping it Real"
Game Changing stock $SHMP
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....
Continue Reading
Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...
Continue Reading
The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...
Continue Reading
Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...
Continue Reading
Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...
Continue Reading
The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...
Continue Reading
Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...
Continue Reading
The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...
Continue Reading
Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...
Continue Reading
GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...
Continue Reading
Top 5 Most Recently Viewed Articles
UCB Highlights Innovations in Generalized Myasthenia Gravis Treatments at AANEM 2024 UCB, a prominent global biopharmaceutical company, is gearing up to present its latest findings in the management of generalized myasthenia gravis (gMG) at the upcoming American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) meeting. The event, which will also feature...
Continue Reading
Lysander Funds Shares New Distributions Estimates Lysander Funds Limited recently made an announcement about the anticipated cash distributions for December 2024 for their exchange-traded funds (ETFs). The focus is on three notable ETFs: Lysander-Slater Preferred Share ActivETF, Lysander-Canso Corporate Treasury ActivETF, and Lysander-Canso Floating Rate ActivETF. Each of...
Continue Reading
Introduction to the Capital Campaign Pace Center for Girls Hillsborough is excited to announce its capital campaign aimed at expanding its capacity and enhancing the support provided to girls in the community. Through dedicated efforts such as education, counseling, and training, this campaign signifies a crucial step towards bettering the future for girls in Hillsborough...
Continue Reading
Bank of America Reports Increased Earnings and Efficiency Bank of America Corp (NASDAQ: BAC) has announced strong financial results for the second quarter, showcasing impressive growth in loans, deposits, and overall profitability. The bank reported a net income of $7.1 billion, a slight increase from $6.9 billion the previous year, along with an earnings per share (EPS)...
Continue Reading
Examining Fair Treatment for Manitex International Shareholders Ademi LLP has launched an investigation into Manitex International, Inc. (NASDAQ: MNTX) due to concerns about possible breaches of fiduciary duty related to its recent transaction with Tadano. This investigation raises important questions about whether shareholders are being treated fairly in the financial...
Continue Reading